Esketamine (CLE-100) vs Zelquistinel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

Esketamine (CLE-100)

Developed by Clexio Biosciences

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT04103892 · Phase 2 · completed

The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.

Reported efficacy

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)

Result source: NCT06340958

Zelquistinel

Developed by Syndeio Biosciences

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT03726658 · Phase 1/2 · completed

The study randomized 226 participants overall to several zelquistinel dose groups or placebo and masked both participants and investigators, but it stated that no power calculation was performed and each comparison was relatively small. The primary MADRS comparisons were clinical measures but were missed, with all reported p-values above 0.05, so the findings provide limited evidence of benefit.

Next expected readout: September 2027 · NCT06547489 (registry estimate)

Reported efficacy

Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2); Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) (Baseline (Day 1) to Day 8): Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) (missed)

Result source: NCT03726658

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEsketamine (CLE-100)Zelquistinel
MADRS, change (acute)-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892
-10.5 vs -10.9+0.4 vs placebo25mg Two Times Per Day · wk 1 · n 38NCT03726658
25 other results
  • -9.5 vs -9.3 25mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -6.7 vs -9.3 10mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -12.8 vs -10.9 3mg Two Times Per Day · wk 1 · n 37 · Phase 1/2 · primary NCT03726658
  • -9.4 vs -9.3 3mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -14.5 vs -13.6 25mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -16.5 vs -16.5 25mg Two Times Per Day · wk 3 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15 vs -16.9 25mg Two Times Per Day · wk 2.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 25mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -15.3 vs -14.7 25mg Two Times Per Day · wk 2 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15.2 vs -14 25mg Two Times Per Day · wk 1.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -14.1 vs -12 25mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.8 vs -13.6 10mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.7 vs -11.6 10mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.6 vs -12 10mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -12.5 vs -13.6 3mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17.3 vs -16.5 3mg Two Times Per Day · wk 3 · n 37 · Phase 1/2 · secondary NCT03726658
  • -18.3 vs -16.9 3mg Two Times Per Day · wk 2.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 3mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17 vs -14.7 3mg Two Times Per Day · wk 2 · n 37 · Phase 1/2 · secondary NCT03726658
  • -15.8 vs -14 3mg Two Times Per Day · wk 1.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13 vs -12 3mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.5 vs -13.6 wk 3 · n 48 · Phase 2 · secondary NCT03586427
  • -12.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427
  • -14.1 vs -13.6 wk 3 · n 52 · Phase 2 · secondary NCT03586427
  • -13.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

Esketamine (CLE-100)
-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892
Zelquistinel
-10.5 vs -10.9+0.4 vs placebo25mg Two Times Per Day · wk 1 · n 38NCT03726658
25 other results
  • -9.5 vs -9.3 25mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -6.7 vs -9.3 10mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -12.8 vs -10.9 3mg Two Times Per Day · wk 1 · n 37 · Phase 1/2 · primary NCT03726658
  • -9.4 vs -9.3 3mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -14.5 vs -13.6 25mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -16.5 vs -16.5 25mg Two Times Per Day · wk 3 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15 vs -16.9 25mg Two Times Per Day · wk 2.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 25mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -15.3 vs -14.7 25mg Two Times Per Day · wk 2 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15.2 vs -14 25mg Two Times Per Day · wk 1.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -14.1 vs -12 25mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.8 vs -13.6 10mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.7 vs -11.6 10mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.6 vs -12 10mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -12.5 vs -13.6 3mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17.3 vs -16.5 3mg Two Times Per Day · wk 3 · n 37 · Phase 1/2 · secondary NCT03726658
  • -18.3 vs -16.9 3mg Two Times Per Day · wk 2.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 3mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17 vs -14.7 3mg Two Times Per Day · wk 2 · n 37 · Phase 1/2 · secondary NCT03726658
  • -15.8 vs -14 3mg Two Times Per Day · wk 1.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13 vs -12 3mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.5 vs -13.6 wk 3 · n 48 · Phase 2 · secondary NCT03586427
  • -12.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427
  • -14.1 vs -13.6 wk 3 · n 52 · Phase 2 · secondary NCT03586427
  • -13.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427

CGI-S, change (acute)

Esketamine (CLE-100)
—Not reported
Zelquistinel
—Not reported

MADRS response

Esketamine (CLE-100)
—Not reported
Zelquistinel
—Not reported

MADRS remission

Esketamine (CLE-100)
—Not reported
Zelquistinel
—Not reported

Relapse (% of patients)

Esketamine (CLE-100)
—Not reported
Zelquistinel
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Esketamine (CLE-100): 4 of 4 rows · Zelquistinel: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEsketamine (CLE-100)Zelquistinel
Dropout rate
7.7%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
8.3%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
7.7%25mg Dailya
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
12.5%25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
3.8%3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
15%3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%AGN-241751 Dose 1
NCT03586427 · Phase 2 · registry result, not featured evidence
8%AGN-241751 Dose 2
NCT03586427 · Phase 2 · registry result, not featured evidence
11.5%AGN-241751 Dose 3
NCT03586427 · Phase 2 · registry result, not featured evidence
8%AGN-241751 Dose 4
NCT03586427 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—25mg Dailya
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
—25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
—10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
—3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
—3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%AGN-241751 Dose 1
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 2
NCT03586427 · Phase 2 · registry result, not featured evidence
1.9%AGN-241751 Dose 3
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 4
NCT03586427 · Phase 2 · registry result, not featured evidence
Serious AEs
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%25mg Dailya
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
0%25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
0%3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
0%3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%AGN-241751 Dose 1
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 2
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 3
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 4
NCT03586427 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
dizziness 30.8% (placebo 0%)
somnolence 15.4% (placebo 0%)
alanine aminotransferase increased 7.7% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
dizziness 13.9% (placebo 0%)
headache 12.5% (placebo 0%)
somnolence 11.1% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
dizziness 18% (placebo 4.1%)
nausea 18% (placebo 0%)
headache 12% (placebo 2%)
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
25mg Dailya
headache 15.4% (placebo 34.1%)
nausea 7.7% (placebo 4.9%)
abnormal dreams 0% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
25mg Two Times Per Day
headache 24.4% (placebo 34.1%)
nausea 14.6% (placebo 4.9%)
abnormal dreams 4.9% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
10mg Daily
headache 19.2% (placebo 34.1%)
nausea 11.5% (placebo 4.9%)
abnormal dreams 0% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
3mg Daily
headache 15.4% (placebo 34.1%)
nausea 7.7% (placebo 4.9%)
abnormal dreams 0% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
3mg Two Times Per Day
headache 14.6% (placebo 34.1%)
abnormal dreams 7.3% (placebo 4.9%)
back pain 7.3% (placebo 2.4%)
NCT03726658 · Phase 1/2 · monotherapy
headache 6.3% (placebo 7.8%)
diarrhea 4.2% (placebo 0%)
dizziness 4.2% (placebo 3.9%)
NCT03586427 · Phase 2 · registry result, not featured evidence
insomnia 10% (placebo 2%)
headache 6% (placebo 7.8%)
nausea 6% (placebo 3.9%)
NCT03586427 · Phase 2 · registry result, not featured evidence
anxiety 5.8% (placebo 0%)
dizziness 5.8% (placebo 3.9%)
headache 5.8% (placebo 7.8%)
NCT03586427 · Phase 2 · registry result, not featured evidence
dizziness 6% (placebo 3.9%)
dry mouth 6% (placebo 2%)
abnormal dreams 4% (placebo 0%)
NCT03586427 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Esketamine (CLE-100)'s landscape · Zelquistinel's landscape